First Trust Dorsey Wright Momentum and Low Volatility ETF News - DVOL

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a...

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a...

Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease

– FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ – –...

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease

MIAMI, July 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative...

Neha Motwani Elected to Longeveron® Board of Directors

MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative...

Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative...

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a...

Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024

MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative...

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a...

Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease

With current HLHS treatment, only 50-60% of infants survive to adolescenceIn ELPIS I Phase 1 clinical trial...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

First Trust Dorsey Wright Momentum and Low Volatility ETF (DVOL)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

DVOL News

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease

Neha Motwani Elected to Longeveron® Board of Directors

Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron® to Attend BIO International Convention 2024

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update

Longeveron Announces Board of Directors Planned Transitions

DVOL Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

First Trust Dorsey Wright Momentum and Low Volatility ETF (DVOL) News

First Trust Dorsey Wright Momentum and Low Volatility ETF (DVOL)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

DVOL News

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease

Neha Motwani Elected to Longeveron® Board of Directors

Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron® to Attend BIO International Convention 2024

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update

Longeveron Announces Board of Directors Planned Transitions

DVOL Discussion

Your Recent History